Bempedoic acid
PERSUADE: triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (NCT07440381)
Study title/design: triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (PERSUADE) (NCT07440381) Trial NCT07440381(not yet recruiting). Estimated study start September 2026. Estimated primary and study completion August 2027. Aim To assess whether early (pre-discharge)…
read more »
CLEAR HIV Trial: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (NCT05488431)
Study title/design: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) (NCT05488431) Trial NCT05488431 (recruiting). Estimated primary and study completion 1 March 2028. Aim To assess the effect of bempedoic acid (BA) on safety and arterial inflammation in…
read more »
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (NCT07474649)
Study title/design: A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (NCT07474649) Trial NCT07474649 (not yet recruiting). Estimated study start 1 June 2026. Estimated primary completion 1 June 2028 and study completion 2 October 2028. Aim To evaluate effect of triple therapy -…
read more »
CLEAR Outcomes: Bempedoic acid effects on major CV outcomes (NCT02993406)
Study title/design: CLEAR Outcomes: Bempedoic acid effects on major CV outcomes (NCT02993406) Trial NCT02993406 (Completed). Aim To determine if bempedoic acid decreases cardiovascular (CV) events in participants with or at high risk of CV disease who are statin intolerant. Study design Phase 3 randomised, double-blind,…
read more »
CLEAR Harmony Open Label Extension: Long term safety and tolerability of bempedoic acid (NCT03067441)
Study title/design: CLEAR Harmony Open Label Extension: Long term safety and tolerability of bempedoic acid (NCT03067441) Trial NCT03067441 (Completed) Aim To determine if bempedoic acid (ETC-1002) is safe and well tolerated in patients at high cardiovascular (CV) risk with elevated LDL-C not adequately controlled by…
read more »
CLEAR Harmony: Long term safety and tolerability of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02666664)
Study title/design: CLEAR Harmony: Long term safety and tolerability of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02666664) Trial NCT02666664 (Completed). Aim To determine if bempedoic acid (ETC-1002) is safe and well tolerated in patients at high cardiovascular (CV) risk with elevated…
read more »
CLEAR Wisdom: Long term efficacy of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02991118)
Study title/design: CLEAR Wisdom: Long term efficacy of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02991118) Trial NCT0299118 (Completed). Aim To determine if bempedoic acid (ETC-1002) is effective in patients at high cardiovascular (CV) risk with elevated LDL-C not adequately controlled by…
read more »
CLEAR Serenity: Bempedoic acid in patients with hyperlipidaemia and statin intolerance (NCT02988115)
Study title/design: CLEAR Serenity: Bempedoic acid in patients with hyperlipidaemia and statin intolerance (NCT02988115) Trial NCT02988115 (Completed). Aim To determine if bempedoic acid (ETC-1002) is effective and safe in patients with elevated LDL-C who are statin intolerant. Study design Phase 3 randomised, double-blind, placebo-controlled study…
read more »
